Atai Beckley advancing BPL-003 nasal spray towards Phase 3 after FDA meeting

AtaiBeckley provided clinical, regulatory, and operational milestones from its 2026 Virtual Investor Day, including the advancement of BPL-003 – mebufotenin benzoate nasal spray – toward Phase 3 initiation in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA. BPL-003, which holds Breakthrough Therapy Designation, is supported by positive Phase 2b results in treatment-resistant depression, or TRD, demonstrating rapid antidepressant effects at Day 2, durable improvements through eight weeks, and higher response and remission rates following an optional second dose in the open-label extension. The company also reaffirmed its cash runway into early 2029, provided updates on its commercial readiness strategy, and outlined continued pipeline progress, including recently announced positive Phase 2a results for EMP-01 and its expectation that VLS-01 will deliver Phase 2 topline data in H2 2026. The company outlined a scalable treatment model without requiring in-session psychotherapy, enabling clinics to incorporate BPL-003 within established care pathways.